Image Source: Unsplash
 

An Introduction

Investors in cannabis stocks react enthusiastically to any hint of cannabis being re-scheduled from that of a Schedule I drug to a less stringently regulated Schedule III drug as it would favorably impact the price of such stocks. Unfortunately, such hope has always dissipated quickly when it is realized that such is not about to occur any time soon. That was exactly what happened last week with the realization the "news" from an anonymous DEA source the previous Friday that the rescheduling would happen by October was, in fact, an unfounded rumor. That hope was replaced with major disappointment and that drove down the prices of all the constituents in the Canadian Cannabis LP Stocks Portfolio by 7.2% last week, on average. 
 

The munKNEE Canadian Cannabis LP Portfolio

Below are the price changes in the constituents of the Portfolio last week, in descending order, and MTD along with any pertinent analyses and commentary:

1. Tilray Brands (TLRY):
   • DOWN 0.5% last week;
   • DOWN 4.9% MTD
   • I Wouldn't Touch Tilray With a 10-Foot Pole
   • Do These 4 New Moves Make Tilray Brands Stock a Buy?
2. Organigram (OGI):
   • DOWN 2.4% last week;
   • UP 20.2% MTD (largely in response to its revenue and earnings report on 8/13)
   • OrganiGram: Fiscal Q3 Earnings Snapshot
3. Cronos Group (CRON):
   • DOWN 4.5% last week;
   • DOWN 4.5% MTD
4. Aurora Cannabis (ACB):
   • DOWN 6.7% last week;
   • UP 5.9% MTD
   • Aurora Cannabis Had a Strong Q1, but Investors Should Expect a Slowdown in Future Quarters
5. Canopy Growth (CGC):
   • DOWN 11.8% last week;
   • DOWN 18.3% MTD
   • Canopy Growth First Quarter 2025 Earnings: Misses Expectations

The Canadian Cannabis LP Portfolio was down 7.2% last week, is now down 4.5% MTD (but is still up 20.9% YTD).

More By This Author:

The +$1T Mega Cap AI Portfolio; Up 29% YTD, Was Flat Last Week
Our Micro/Small Cap AI Stocks Portfolio Jumped 11.5% Last Week
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week